Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621010 · ClinicalTrials.gov registry record · Phase 1
Safety Study of CTS21166 to Treat Alzheimer Disease
A Phase 1 study of Alzheimers Disease, sponsored by CoMentis.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT00621010: Completed Phase 1 study of Alzheimers Disease, sponsored by CoMentis.
NCT00621010 is a Phase 1 study of Alzheimers Disease that has completed, run by CoMentis. The registered enrollment target is 56 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00621010, a Phase 1 study of Alzheimers Disease, has completed, sponsored by CoMentis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers
Conditions Studied
Interventions
- DRUG CTS21166 (ZPQ-21166)
Study Locations (1)
Utah
- Lifetree Clinical Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
What the finished NCT00621010 record still lists
NCT00621010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which CTS21166 (ZPQ-21166) is the first listed.
NCT00621010 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT00621010 about?
NCT00621010 is a clinical study titled "Safety Study of CTS21166 to Treat Alzheimer Disease". This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers
What is the current status of trial NCT00621010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-06. Estimated completion is 2008-02.
What conditions does trial NCT00621010 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00621010?
The interventions under investigation include: CTS21166 (ZPQ-21166) (DRUG).
Who is sponsoring clinical trial NCT00621010?
This trial is sponsored by CoMentis, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00621010 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00621010's enrollment target sits among peer trials
56 91st of 147 higher than 57 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia